Ligand Pharmaceuticals Incorporated (LGND) Q2 FY25 Earnings Call

57% royalty-revenue growth and 2025 adjusted-EPS guidance of $6.70-$7.00 indicate stronger portfolio momentum.

Q2 FY25 results, source: company transcript and SEC filings
QuarterQ2 FY25
Call date2025-08-07
Length44 minutes
EPS$0.24
EPS consensus$0.21
Revenue$47.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26 · Q4 FY25

All LGND earnings · Back to LGND overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.